Search

Your search keyword '"Mäkisalo, Heikki"' showing total 127 results
Start Over Author "Mäkisalo, Heikki" Search Limiters Full Text
127 results on '"Mäkisalo, Heikki"'

1. NGS of brush cytology samples improves the detection of high-grade dysplasia and cholangiocarcinoma in patients with primary sclerosing cholangitis: A retrospective and prospective study

Author

Boyd, Sonja, primary, Mustamäki, Taru, additional, Sjöblom, Nelli, additional, Nordin, Arno, additional, Tenca, Andrea, additional, Jokelainen, Kalle, additional, Rantapero, Tommi, additional, Liuksiala, Thomas, additional, Lahtinen, Laura, additional, Kuopio, Teijo, additional, Kytölä, Soili, additional, Mäkisalo, Heikki, additional, Färkkilä, Martti, additional, and Arola, Johanna, additional

Published
2024
Full Text
View/download PDF

3. Treatment response of colorectal cancer liver metastases to neoadjuvant or conversion therapy: a prospective multicentre follow-up study using MRI, diffusion-weighted imaging and 1H-MR spectroscopy compared with histology (subgroup in the RAXO trial)

Author

Mäkisalo, Heikki, Huuhtanen, Riikka, Kosunen, Juhani, Leppä, Sirpa, Bono, Petri, Mattson, Johanna, Österlund, Emerik, Penttinen, Heidi, Mäkelä, Siru, Carpén, Olli, Timonen, Marjut, Lehtomäki, Kaisa, Salminen, Veera, Paunu, Niina, Vornanen, Martine, Lasse, Nieminen, Heervä, Eetu, Korkeila, Eija, Sutinen, Eija, Lavonius, Maija, Sundström, Jari, Mäkinen, Markus, Poussa, Tuija, Uutela, A., Ovissi, A., Hakkarainen, A., Ristimäki, A., Lundbom, N., Kallio, R., Soveri, L.M., Salminen, T., Ålgars, A., Halonen, P., Ristamäki, R., Nordin, A., Blanco Sequeiros, R., Rinta-Kiikka, I., Lantto, E., Virtanen, J., Pääkkö, E., Liukkonen, E., Saunavaara, J., Ryymin, P., Lammentausta, E., Osterlund, P., and Isoniemi, H.

Published
2021
Full Text
View/download PDF

5. High immune cell infiltration predicts improved survival in cholangiocarcinoma.

Author

Wirta, Erkki-Ville, Szeto, Säde, Koppatz, Hanna, Nordin, Arno, Mäkisalo, Heikki, Arola, Johanna, Sirén, Jukka, Ahtiainen, Maarit, Böhm, Jan, Mecklin, Jukka-Pekka, Sallinen, Ville, and Seppälä, Toni T.

Subjects
CHOLANGIOCARCINOMA, PROGRAMMED cell death 1 receptors, PROGRAMMED death-ligand 1, OVERALL survival, PROGNOSIS
Abstract

Background: Antitumoral immune response has a crucial role in constraining cancer. However, previous studies on cholangiocarcinoma (CCA), a rare and aggressive cancer, have reported contradictory findings on the prognostic impact of tumorinfiltrating T-lymphocytes. We aimed to clarify the effect of tumor-infiltrating CD3+ and CD8+ lymphocytes and PD-1/PD-L1 expression on CCA prognosis. Methods: CD3+, CD8+, and PD-1+ lymphocyte densities, as well as PD-L1 expression rate were analyzed from stained tissue microarray samples from the tumor center and invasive margin of 47 cholangiocarcinomas. The association of CD3+ and CD8+ based Immune cell score (ICS) and its components with overall survival was evaluated, adjusting for age, sex, TNM stage, radicality of surgery, tumor location, and PD-L1 expression on immune cells. Results: Low ICS was a strong independent prognostic factor for worse overall survival (Hazard ratio 9.27, 95% confidence interval 2.72-31.64, P<0.001). Among the ICS components, high CD8+ lymphocyte infiltration at the tumor center had the most evident impact on patient outcome. PD-1 and PD-L1 expression on immune cells did not have a significant impact on overall survival alone; however, PD-L1 positivity seemed to impair survival for ICSlow subgroup. Conclusion: Identifying patient subgroups that could benefit from immunotherapy with PD-1/PD-L1 pathway blockade may help improve treatment strategies for this aggressive cancer. Our findings highlight the importance of evaluating the immune contexture in cholangiocarcinoma, as ICS serves as a strong independent prognostic and selective factor for patients who might benefit from immunotherapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Timing of Organ Procurement From Brain-Dead Donors Associates With Short- and Long-Term Outcomes After Liver Transplantation

Author

Eerola, Verner, Helanterä, Ilkka, Åberg, Fredrik, Lempinen, Marko, Mäkisalo, Heikki, Nordin, Arno, Isoniemi, Helena, Sallinen, Ville, Clinicum, HUS Abdominal Center, IV kirurgian klinikka, Pertti Panula / Principal Investigator, Department of Anatomy, and Helsinki University Hospital Area

Subjects
organ allocation, liver allograft function, Transplantation, Tissue and Organ Procurement, DURATION, graft survival, liver transplant dysfunction, Brain, donor hepatectomy, 3126 Surgery, anesthesiology, intensive care, radiology, Severity of Illness Index, Liver Transplantation, TIME, End Stage Liver Disease, ACTIVATION, procurement surgery, SURVIVAL, Humans, brain death, FAILURE
Abstract

Brain death-induced cytokine storm is thought to harm transplantable organs. However, longer procurement times have been associated with non-inferior or better outcomes in kidney, heart, and lung transplants, while optimal procurement time for liver allografts is unknown. Our aim was to analyze the association of time interval from brain death to organ procurement with liver allograft outcomes in two nationwide cohorts. The association of procurement interval with graft survival and short-term complications was analysed in multivariable models. Altogether 643 and 58,017 orthotopic liver transplantations from brain-dead donors were included from Finland between June 2004 and December 2017 and the US between January 2008 and August 2018, respectively. Median time from brain death to organ procurement was 10.5 h in Finland and 34.6 h in the US. Longer interval associated with better graft survival (non-linearly, p = 0.016) and less acute rejections (OR 0.935 95% CI 0.894–0.978) in the US cohort, and better early allograft function (p = 0.005; Beta −0.048 95% CI −0.085 −(−0.011)) in the Finnish cohort, in multivariable models adjusted with Donor Risk Index, recipient age, Model for End-Stage Liver Disease and indication for transplantation. Progressive liver injury after brain death is unlikely. Rushing to recover seems unnecessary; rest and repair might prove beneficial.

Published
2022

8. HCC recurrence in HCV‐infected patients after liver transplantation: SiLVER Study reveals benefits of sirolimus in combination with CNIs – a post‐hoc analysis

Author

Werner, Jens M., Hornung, Matthias, Krah, Rubertha, Götz, Markus, Schnitzbauer, Andreas A., Schlitt, Hans J., Geissler, Edward K., Zülke, Carl, Lamby, Philipp E., Proneth, Andrea, Duvoux, Christophe, Burra, Patrizia, Jauch, Karl‐Walter, Rentsch, Markus, Ganten, Tom M., Schmidt, Jan, Settmacher, Utz, Heise, Michael, Rossi, Giorgio, Cillo, Umberto, Kneteman, Norman, Adam, René, Hoek, Bart, Bachellier, Philippe, Wolf, Philippe, Rostaing, Lionel, Bechstein, Wolf O., Rizell, Magnus, Powell, James, Hidalgo, Ernest, Gugenheim, Jean, Wolters, Heiner, Brockmann, Jens, Roy, André, Mutzbauer, Ingrid, Schlitt, Angela, Beckebaum, Susanne, Graeb, Christian, Nadalin, Silvio, Valente, Umberto, Turrión, Victor Sánchez, Jamieson, Neville, Scholz, Tim, Colledan, Michele, Fändrich, Fred, Becker, Thomas, Söderdahl, Gunnar, Chazouillères, Olivier, Mäkisalo, Heikki, Pageaux, Georges‐Philippe, Steininger, Rudolf, Soliman, Thomas, Jong, Koert P., Pirenne, Jacques, Margreiter, Raimund, Pratschke, Johann, Pinna, Antonio D., Hauss, Johann, Schreiber, Stefan, Strasser, Simone, Klempnauer, Jürgen, Troisi, Roberto I., Bhoori, Sherrie, Lerut, Jan, Bilbao, Itxarone, Klein, Christian G., Königsrainer, Alfred, Otto, Gerd, Mazzaferro, Vincenzo, Neuhaus, Peter, Werner, J, Hornung, M, Krah, R, Gotz, M, Schnitzbauer, A, Schlitt, H, Geissler, E, Zulke, C, Lamby, P, Proneth, A, Duvoux, C, Burra, P, Jauch, K, Rentsch, M, Ganten, T, Schmidt, J, Settmacher, U, Heise, M, Rossi, G, Cillo, U, Kneteman, N, Adam, R, Hoek, B, Bachellier, P, Wolf, P, Rostaing, L, Bechstein, W, Rizell, M, Powell, J, Hidalgo, E, Gugenheim, J, Wolters, H, Brockmann, J, Roy, A, Mutzbauer, I, Schlitt, A, Beckebaum, S, Graeb, C, Nadalin, S, Valente, U, Turrion, V, Jamieson, N, Scholz, T, Colledan, M, Fandrich, F, Becker, T, Soderdahl, G, Chazouilleres, O, Makisalo, H, Pageaux, G, Steininger, R, Soliman, T, Jong, K, Pirenne, J, Margreiter, R, Pratschke, J, Pinna, A, Hauss, J, Schreiber, S, Strasser, S, Klempnauer, J, Troisi, R, Bhoori, S, Lerut, J, Bilbao, I, Klein, C, Konigsrainer, A, Otto, G, Mazzaferro, V, and Neuhaus, P

Subjects
Silver Study, medicine.medical_specialty, Carcinoma, Hepatocellular, Silver, direct-acting antiviral agents, medicine.medical_treatment, 610 Medizin, Subgroup analysis, 030230 surgery, Liver transplantation, Gastroenterology, Group B, 03 medical and health sciences, HEPATOCELLULAR-CARCINOMA, hepatitis C virus infection, hepatocellular carcinoma, liver transplantation, 0302 clinical medicine, Internal medicine, Post-hoc analysis, medicine, Humans, Sirolimus, direct-acting antiviral agent, ddc:610, Transplantation, business.industry, Liver Neoplasms, Immunosuppression, medicine.disease, Hepatitis C, digestive system diseases, Calcineurin, Hepatocellular carcinoma, 030211 gastroenterology & hepatology, Neoplasm Recurrence, Local, business, medicine.drug
Abstract

Factors affecting outcomes in liver transplant (LTx) recipients with hepatocellular carcinoma (HCC) and hepatitis C viral (HCV) infection include the choice of immunosuppression. Here, we analyzed the HCV+ subgroup of patients from the randomized controlled, international SiLVER Study. We performed a post hoc analysis of 166 HCV+ SiLVER Study patients regarding HCC outcome after LTx. Control patients (group A: n=88) received mTOR inhibitor (mTORi)-free, calcineurin inhibitor (CNI)-based versus sirolimus-based immunosuppression (group B: n=78). We found no significant difference regarding HCV-RNA titers between group A and B. Since no effect in group B could be due to variable sirolimus dosing, we split group B into patients receiving sirolimus-based immunosuppression+CNIs for >50% (B1; n=44) or

Published
2020

10. Treatment response of colorectal cancer liver metastases to neoadjuvant or conversion therapy: a prospective multicentre follow-up study using MRI, diffusion-weighted imaging and 1H-MR spectroscopy compared with histology (subgroup in the RAXO trial)

Author

Uutela, A., primary, Ovissi, A., additional, Hakkarainen, A., additional, Ristimäki, A., additional, Lundbom, N., additional, Kallio, R., additional, Soveri, L.M., additional, Salminen, T., additional, Ålgars, A., additional, Halonen, P., additional, Ristamäki, R., additional, Nordin, A., additional, Blanco Sequeiros, R., additional, Rinta-Kiikka, I., additional, Lantto, E., additional, Virtanen, J., additional, Pääkkö, E., additional, Liukkonen, E., additional, Saunavaara, J., additional, Ryymin, P., additional, Lammentausta, E., additional, Osterlund, P., additional, Isoniemi, H., additional, Mäkisalo, Heikki, additional, Huuhtanen, Riikka, additional, Kosunen, Juhani, additional, Leppä, Sirpa, additional, Bono, Petri, additional, Mattson, Johanna, additional, Österlund, Emerik, additional, Penttinen, Heidi, additional, Mäkelä, Siru, additional, Carpén, Olli, additional, Timonen, Marjut, additional, Lehtomäki, Kaisa, additional, Salminen, Veera, additional, Paunu, Niina, additional, Vornanen, Martine, additional, Lasse, Nieminen, additional, Heervä, Eetu, additional, Korkeila, Eija, additional, Sutinen, Eija, additional, Lavonius, Maija, additional, Sundström, Jari, additional, Mäkinen, Markus, additional, and Poussa, Tuija, additional

Published
2021
Full Text
View/download PDF

11. Sopeutuminen - alistumista vai selviytymistä?

Author

Rapola, Janne, Heikinheimo, Oskari, Rovasalo, Aki, Mäkisalo, Heikki, Sisätautien osasto, Clinicum, Naistenklinikka, HUS Naistentaudit ja synnykset, HUS Vatsakeskus, and IV kirurgian klinikka

Subjects
3141 Terveystiede, Adaptation, Psychological, Environment, Pandemics, Illness Behavior
Abstract

Teema : sopeutuminen. Kuuntele podcast jossa Kari Hevossaari keskustelee joulunumeron päätoimittajan Janne Rapolan kanssa numeron teemasta sopeutumisesta.

Published
2021

16. Randomised sham-controlled double-blind trial evaluating remote ischaemic preconditioning in solid organ transplantation: a study protocol for the RIPTRANS trial

Author

Uutela, Aki, primary, Helanterä, Ilkka, additional, Lemström, Karl, additional, Passov, Arie, additional, Syrjälä, Simo, additional, Åberg, Fredrik, additional, Mäkisalo, Heikki, additional, Nordin, Arno, additional, Lempinen, Marko, additional, and Sallinen, Ville, additional

Published
2020
Full Text
View/download PDF

22. Maksaportin sappitiesyöpä eli Klatskinin tuumori

Author

Sallinen, Ville, Peltola, Katriina, Mäkisalo, Heikki, Pertti Panula / Vastuullinen tutkija, IV kirurgian klinikka, Clinicum, Syöpätautien osasto, HUS Syöpäkeskus, and HUS Vatsakeskus

Subjects
3122 Syöpätaudit, 3126 Kirurgia, anestesiologia, tehohoito, radiologia
Abstract

Teema : maksa- , haima- ja sappitiekirurgia. English summary

Published
2019

23. Kun Morgagni ja Caesar tapasivat

Author

Andersson, Saana, Mäkisalo, Heikki, HUS Sydän- ja keuhkokeskus, Sydän ja rintaelinkirurgia, Kirurgian osasto, HUS Vatsakeskus, and IV kirurgian klinikka

Subjects
3126 Kirurgia, anestesiologia, tehohoito, radiologia
Abstract

Teema : syntymä

Published
2019

27. Lääkärien pariutumisen motiivit

Author

Mustonen, Pekka, Pankakoski, Maiju, Arola, Johanna, Höckerstedt, Krister, Mäkisalo, Heikki, Saarela, Lauri, Lindgren, Leena, HUSLAB, Patologian osasto, Medicum, IV kirurgian klinikka, Clinicum, and HUS Vatsakeskus

Subjects
5144 Sosiaalipsykologia
Abstract

Teema : motivaatio

Published
2018

28. Motivoiko joulunumero?

Author

Höckerstedt, Krister, Arola, Johanna, Lindgren, Leena, Mustonen, Pekka, Mäkisalo, Heikki, Saarela, Lauri, IV kirurgian klinikka, Kirurgian osasto, Clinicum, Patologian osasto, Medicum, and HUS Vatsakeskus

Subjects
3111 Biolääketieteet, 3112 Neurotieteet
Abstract

Teema : motivaatio

Published
2018

30. Occurrence of newly discovered human polyomaviruses in skin of liver transplant recipients and their relation with squamous cell carcinoma in situ and actinic keratosis – a single‐center cohort study

Author

Wang, Yilin, primary, Keinonen, Anne, additional, Koskenmies, Sari, additional, Pitkänen, Sari, additional, Fyhrquist, Nanna, additional, Sadeghi, Mohammadreza, additional, Mäkisalo, Heikki, additional, Söderlund‐Venermo, Maria, additional, and Hedman, Klaus, additional

Published
2019
Full Text
View/download PDF

31. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma

Author

Roy Andre, Rostaing Lionel, Rossi Giorgio, Rizell Magnus, Pirenne Jacques, Pinna Antonio D, Pageaux Georges-Philippe, Otto Gerd, Mutzbauer Ingrid, Mazzaferro Vincenzo, Margreiter Raimund, Mäkisalo Heikki, Lerut Jan P, Lamby Philipp E, Königsrainer Alfred, Jamieson Neville, Hidalgo Ernest, Heise Michael, Hauss Johann P, Gugenheim Jean, Fändrich Fred, Colledan Michele, Cillo Umberto, Chazouillères Olivier, Beckebaum Susanne, Becker Thomas, Bechstein Wolf O, Adam Rene, Kneteman Norman M, Duvoux Christophe, de Jong Koert P, Burra Patrizia, Bilbao Itxarone, Rochon Justine, Graeb Christian, Zuelke Carl, Schnitzbauer Andreas A, Turrion Victor, Schmidt Jan, Troisi Roberto I, van Hoek Bart, Valente Umberto, Wolf Philippe, Wolters Heiner, Mirza Darius F, Scholz Tim, Steininger Rudolf, Soderdahl Gunnar, Strasser Simone I, Jauch Karl-Walter, Neuhaus Peter, Schlitt Hans J, and Geissler Edward K

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background The potential anti-cancer effects of mammalian target of rapamycin (mTOR) inhibitors are being intensively studied. To date, however, few randomised clinical trials (RCT) have been performed to demonstrate anti-neoplastic effects in the pure oncology setting, and at present, no oncology endpoint-directed RCT has been reported in the high-malignancy risk population of immunosuppressed transplant recipients. Interestingly, since mTOR inhibitors have both immunosuppressive and anti-cancer effects, they have the potential to simultaneously protect against immunologic graft loss and tumour development. Therefore, we designed a prospective RCT to determine if the mTOR inhibitor sirolimus can improve hepatocellular carcinoma (HCC)-free patient survival in liver transplant (LT) recipients with a pre-transplant diagnosis of HCC. Methods/Design The study is an open-labelled, randomised, RCT comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing LT for HCC. Patients with a histologically confirmed HCC diagnosis are randomised into 2 groups within 4-6 weeks after LT; one arm is maintained on a centre-specific mTOR-inhibitor-free immunosuppressive protocol and the second arm is maintained on a centre-specific mTOR-inhibitor-free immunosuppressive protocol for the first 4-6 weeks, at which time sirolimus is initiated. A 21/2 -year recruitment phase is planned with a 5-year follow-up, testing HCC-free survival as the primary endpoint. Our hypothesis is that sirolimus use in the second arm of the study will improve HCC-free survival. The study is a non-commercial investigator-initiated trial (IIT) sponsored by the University Hospital Regensburg and is endorsed by the European Liver and Intestine Transplant Association; 13 countries within Europe, Canada and Australia are participating. Discussion If our hypothesis is correct that mTOR inhibition can reduce HCC tumour growth while simultaneously providing immunosuppression to protect the liver allograft from rejection, patients should experience less post-transplant problems with HCC recurrence, and therefore could expect a longer and better quality of life. A positive outcome will likely change the standard of posttransplant immunosuppressive care for LT patients with HCC. Trial Register Trial registered at http://www.clinicaltrials.gov: NCT00355862 (EudraCT Number: 2005-005362-36)

Published
2010
Full Text
View/download PDF

33. Maksansiirto - voiko siirtoaiheita laajentaa?

Author

Isoniemi, Helena, Mäkisalo, Heikki, Nordin, Arno, Clinicum, IV kirurgian klinikka, and HUS Vatsakeskus

Subjects
Liver Cirrhosis, 3121 Yleislääketiede, sisätaudit ja muut kliiniset lääketieteet, Non-alcoholic Fatty Liver Disease, Contraindications, Patient Selection, Liver Neoplasms, 3126 Kirurgia, anestesiologia, tehohoito, radiologia, +surgery, Hepatitis, Liver Transplantation
Abstract

Teema : elinsiirrot. English summary

Published
2017

34. Elinkauppa - elinsiirrot rikollisten käsissä

Author

Mäkisalo, Heikki, IV kirurgian klinikka, Clinicum, Kirurgian osasto, and HUS Vatsakeskus

Subjects
Tissue and Organ Procurement, Treatment Outcome, 3126 Kirurgia, anestesiologia, tehohoito, radiologia, Living Donors, Organ Trafficking, +ethics, Organ Transplantation, +statistics & numerical data
Abstract

Teema : elinsiirrot. English summary

Published
2017

35. Nuoren naisen maksavamma

Author

Saarinen, Tuure, Mäkisalo, Heikki, Clinicum, II kirurgian klinikka, Kirurgian osasto, IV kirurgian klinikka, and HUS Vatsakeskus

Subjects
3121 Yleislääketiede, sisätaudit ja muut kliiniset lääketieteet, Adolescent, Critical Care, Liver, +therapy, +diagnosis, Accidents, +injuries, 3126 Kirurgia, anestesiologia, tehohoito, radiologia, Female, Abdominal Injuries, Horses
Abstract

English summary

Published
2017

36. Suomi 125 vuotta - elinsiirtoja edelleen?

Author

Jalanko, Hannu, Miettinen, Susanna, Mäkisalo, Heikki, Lääketieteen ja biotieteiden tiedekunta - Faculty of Medicine and Life Sciences, Tampere University, Lastenklinikka, Lastentautien yksikkö, Clinicum, IV kirurgian klinikka, Kirurgian osasto, HUS Lasten ja nuorten sairaudet, and HUS Vatsakeskus

Subjects
3126 Kirurgia, anestesiologia, tehohoito, radiologia, Organ Transplantation, +trends, Biokemia, solu- ja molekyylibiologia - Biochemistry, cell and molecular biology
Abstract

Teema : elinsiirrot

Published
2017

37. Kyykauden kuva

Author

Mäkisalo, Heikki, IV kirurgian klinikka, Clinicum, Kirurgian osasto, and HUS Vatsakeskus

Subjects
+adverse effects, 3121 Yleislääketiede, sisätaudit ja muut kliiniset lääketieteet, +therapy, +complications, Snake Bites, Viper Venoms
Published
2017

40. Mitä teen, kun löydän maksasta pesäkkeen?

Author

Mäkisalo, Heikki, Lantto, Eila, IV kirurgian klinikka, Clinicum, Kirurgian osasto, and Diagnostis-terapeuttinen osasto

Subjects
+pathology, 3121 Yleislääketiede, sisätaudit ja muut kliiniset lääketieteet, Bile Duct Neoplasms, Liver, Cysts, Focal Nodular Hyperplasia, Liver Diseases, +diagnosis, Liver Neoplasms, 3126 Kirurgia, anestesiologia, tehohoito, radiologia, Hemangioma, Adenoma, Liver Cell
Abstract

Teema : hepatologia. English summary

Published
2016

41. Post-transplant Merkel Cell Carcinoma

Author

Koljonen, Virve, Sahi, Helka, Bohling, Tom, Mäkisalo, Heikki, Clinicum, Plastiikkakirurgian yksikkö, Department of Surgery, IV kirurgian klinikka, Department of Pathology, Medicum, and Tom Böhling / Principal Investigator

Subjects
skin, T-ANTIGEN, KIDNEY, 3121 General medicine, internal medicine and other clinical medicine, 3122 Cancers, neuroendocrine carcinoma, outcome, food and beverages, RENAL-TRANSPLANT RECIPIENTS, POLYOMAVIRUS, DIAGNOSIS, LUNG, malignancy
Abstract

Malignant tumours are the foremost complications of immunosuppressive treatment. They are a major challenge for organ transplant recipients and their treating physicians. This paper reviews the aetiology and current treatment of an unusual neuroendocrine skin cancer, Merkel cell carcinoma (MCC), caused by a Merkel cell polyomavirus infection. MCC occurs more frequently than expected in immunosuppressed subjects, especially in organ transplant recipients. The current literature comprises reports of 79 organ transplant recipients with MCC. The risk of MCC in organ transplant recipients is increased up to 66-182-fold compared with the general population. In addition to the increased risk of developing MCC, immunosuppressed individuals have poorer MCC-specific survival. The aim of this review article is to familiarize organ transplant doctors with this unique and clinically challenging skin cancer, and to provide recent data on the diagnosis and current treatment recommendations for an immunosuppressed population.

Published
2016

42. Vaaralliset eläimet

Author

Koljonen, Virve, Mäkisalo, Heikki, Söderlund, Tim, Gissler, Mika, Clinicum, Plastiikkakirurgian yksikkö, Kirurgian osasto, IV kirurgian klinikka, and I kirurgian klinikka (Töölö)

Subjects
+epidemiology, GeneralLiterature_INTRODUCTORYANDSURVEY, Poisoning, 3126 Kirurgia, anestesiologia, tehohoito, radiologia, ComputingMethodologies_DOCUMENTANDTEXTPROCESSING, +complications, Animals, Wounds and Injuries, Bites and Stings, Infection, GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries)
Abstract

English summary

Published
2016

44. Acute liver failure after valproate exposure in patients withPOLG1mutations and the prognosis after liver transplantation

Author

Hynynen, Johanna, primary, Komulainen, Tuomas, additional, Tukiainen, Eija, additional, Nordin, Arno, additional, Arola, Johanna, additional, Kälviäinen, Reetta, additional, Jutila, Leena, additional, Röyttä, Matias, additional, Hinttala, Reetta, additional, Majamaa, Kari, additional, Mäkisalo, Heikki, additional, and Uusimaa, Johanna, additional

Published
2014
Full Text
View/download PDF

46. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma

Author

Schnitzbauer, Andreas A, primary, Zuelke, Carl, additional, Graeb, Christian, additional, Rochon, Justine, additional, Bilbao, Itxarone, additional, Burra, Patrizia, additional, de Jong, Koert P, additional, Duvoux, Christophe, additional, Kneteman, Norman M, additional, Adam, Rene, additional, Bechstein, Wolf O, additional, Becker, Thomas, additional, Beckebaum, Susanne, additional, Chazouillères, Olivier, additional, Cillo, Umberto, additional, Colledan, Michele, additional, Fändrich, Fred, additional, Gugenheim, Jean, additional, Hauss, Johann P, additional, Heise, Michael, additional, Hidalgo, Ernest, additional, Jamieson, Neville, additional, Königsrainer, Alfred, additional, Lamby, Philipp E, additional, Lerut, Jan P, additional, Mäkisalo, Heikki, additional, Margreiter, Raimund, additional, Mazzaferro, Vincenzo, additional, Mutzbauer, Ingrid, additional, Otto, Gerd, additional, Pageaux, Georges-Philippe, additional, Pinna, Antonio D, additional, Pirenne, Jacques, additional, Rizell, Magnus, additional, Rossi, Giorgio, additional, Rostaing, Lionel, additional, Roy, Andre, additional, Turrion, Victor Sanchez, additional, Schmidt, Jan, additional, Troisi, Roberto I, additional, van Hoek, Bart, additional, Valente, Umberto, additional, Wolf, Philippe, additional, Wolters, Heiner, additional, Mirza, Darius F, additional, Scholz, Tim, additional, Steininger, Rudolf, additional, Soderdahl, Gunnar, additional, Strasser, Simone I, additional, Jauch, Karl-Walter, additional, Neuhaus, Peter, additional, Schlitt, Hans J, additional, and Geissler, Edward K, additional

Published
2010
Full Text
View/download PDF

49. ACUTE EFFECT OF ALCOHOL ON ANDROGENS IN PREMENOPAUSAL WOMEN.

Author

Sarkola, Taisto, Fukunaga, Tatsushige, Mäkisalo, Heikki, and Peter Eriksson, C. J.

Subjects
ALCOHOL research, ALCOHOL drinking, ANDROGENS, TESTOSTERONE, ANDROSTENEDIONE, HYPERANDROGENISM, PERIMENOPAUSE
Abstract

The aim of the present study was to investigate the effect of alcohol on androgen levels among premenopausal women. Eighty-seven women in the mid-cycle phase of the menstrual cycle, 47 of whom used oral contraceptives (OC+), were included in the study. The range for reported alcohol consumption was 0–4 drinks/day. The total testosterone levels were significantly higher after alcohol intake (0.5 g/kg) than after placebo at 45 min and 90 min from the start of drinking among both OC– and OC+ subjects. This effect was also seen in the free testosterone fraction. The effect on testosterone was more prominent among OC+ subjects. Androstenedione levels were significantly lowered and the testosterone:androstenedione ratio significantly elevated by alcohol among both OC– and OC+ subjects. No effect of alcohol on dehydroepiandrosterone or dihydrotestosterone levels was observed. A positive correlation was observed between the change in testosterone levels and the change in androstenedione levels during placebo conditions. The correlation was significantly reduced during alcohol conditions among OC+ subjects, indicating an increased androstenedione to testosterone conversion. No significant dose (0.34, 0.68 and 1.02 g/kg) or time (45, 90 and 150 min) effects on total testosterone were observed in a substudy involving 10 OC+ subjects. The present results suggest that the testosterone effect is related to the zero-order mechanism of ethanol oxidation. The observed testosterone and androstenedione effects are suggested to be the result of an increased androstenedione to testosterone conversion in the liver caused by the alcohol-mediated elevation in the [NADH]:[NAD+] ratio. The present findings may be relevant in the development of hyperandrogenism and loss of female sexual characteristics associated with heavy alcohol consumption. [ABSTRACT FROM PUBLISHER]

Published
2000
Full Text
View/download PDF

50. Predictors of insufficient recanalization and portal hypertensive complications after treatment of non-cirrhotic, non-malignant portal vein thrombosis – a population-based study

Author

Lemma, Aurora, Åberg, Fredrik, Mäkisalo, Heikki, Pirkka Vikatmaa, Mentula, Panu, Leppäniemi, Ari, and Sallinen, Ville

Subjects
3. Good health
Abstract

In acute portal vein thrombosis (PVT), a six-month anticoagulation treatment achieves complete recanalization in only 35%–45% of patients, but the predictors of poor treatment responses are unclear. We examined treatment outcomes in PVT and aimed to identify predictors of incomplete recanalization and portal hypertensive complications. This retrospective study comprised patients diagnosed with PVT between 2006 and 2015. Key exclusion criteria were liver cirrhosis, malignancy, and age

Catalog

Books, media, physical & digital resources
See catalog results